Bristol Heart Institute, University of Bristol, Bristol BS2 8ED, UK; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
Laboratory of Precision NanoMedicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel.
Mol Ther. 2021 Jul 7;29(7):2239-2252. doi: 10.1016/j.ymthe.2021.03.015. Epub 2021 Mar 18.
MicroRNAs (miRNAs) regulate gene expression by post-transcriptional inhibition of target genes. Proangiogenic small extracellular vesicles (sEVs; popularly identified with the name "exosomes") with a composite cargo of miRNAs are secreted by cultured stem cells and present in human biological fluids. Lipid nanoparticles (LNPs) represent an advanced platform for clinically approved delivery of RNA therapeutics. In this study, we aimed to (1) identify the miRNAs responsible for sEV-induced angiogenesis; (2) develop the prototype of bioinspired "artificial exosomes" (AEs) combining LNPs with a proangiogenic miRNA, and (3) validate the angiogenic potential of the bioinspired AEs. We previously reported that human sEVs from bone marrow (BM)-CD34 cells and pericardial fluid (PF) are proangiogenic. Here, we have shown that sEVs secreted from saphenous vein pericytes and BM mesenchymal stem cells also promote angiogenesis. Analysis of miRNA datasets available in-house or datamined from GEO identified the let-7 family as common miRNA signature of the proangiogenic sEVs. LNPs with either hsa-let-7b-5p or cyanine 5 (Cy5)-conjugated Caenorhabditis elegans miR-39 (Cy5-cel-miR-39; control miRNA) were prepared using microfluidic micromixing. let-7b-5p-AEs did not cause toxicity and transferred functionally active let-7b-5p to recipient endothelial cells (ECs). let-7b-AEs also improved EC survival under hypoxia and angiogenesis in vitro and in vivo. Bioinspired proangiogenic AEs could be further developed into innovative nanomedicine products targeting ischemic diseases.
微小 RNA(miRNAs)通过靶基因的转录后抑制来调节基因表达。富含 miRNAs 的促血管生成小细胞外囊泡(sEVs;通常被命名为“外泌体”)是由培养的干细胞分泌的,存在于人体生物体液中。脂质纳米颗粒(LNPs)是一种先进的 RNA 治疗药物临床批准的递送平台。在这项研究中,我们旨在:(1)鉴定负责 sEV 诱导血管生成的 miRNAs;(2)开发结合 LNPs 和促血管生成 miRNA 的仿生“人工外泌体”(AE)的原型;(3)验证仿生 AE 的血管生成潜力。我们之前报道过,骨髓(BM)-CD34 细胞和心包液(PF)来源的 sEV 具有促血管生成作用。在这里,我们已经表明,来源于大隐静脉周细胞和 BM 间充质干细胞的 sEV 也能促进血管生成。对内部可用的 miRNA 数据集或从 GEO 挖掘的数据进行分析,确定了 let-7 家族是促血管生成 sEV 的常见 miRNA 特征。使用微流控微混合制备了载有 hsa-let-7b-5p 或 Cy5 标记的秀丽隐杆线虫 miR-39(Cy5-cel-miR-39;对照 miRNA)的 LNPs。let-7b-5p-AE 不会引起毒性,并将功能活性的 let-7b-5p 转导至受体内皮细胞(EC)。let-7b-AE 还可改善缺氧条件下 EC 的存活和体内外血管生成。仿生促血管生成 AE 可进一步开发为针对缺血性疾病的创新纳米医学产品。